CardioKinetix Closes $48M Series E Financing for Heart Failure Therapy

CardioKinetix Inc announced that it has already completed the $23M second tranche financing, bringing the total amount to $48M in order to advance their programs to bring their catheter-based heart failure therapy to more and more patients around the world.

As quoted in the press release:

This financing follows the Company’s achievement of several recent milestones including the treatment of more than 100 patients with the Parachute(R) device, enrollment in PARACHUTE IV, the Company’s U.S. randomized pivotal trial, initiation of European commercialization, and receipt of a dedicated German reimbursement code.

Click here to read the full CardioKinetix Inc press release.